Kelly Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kelly Chen has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Abigail Volk
Department of Psychology, The Ohio State University, Columbus, USA
1 shared publicationAidan C. Johantges
Department of Neuroscience, The Ohio State University, Columbus, USA
1 shared publicationAlec H. Marshall
Department of Neuroscience, The Ohio State University, Columbus, USA
1 shared publication- Ana Preda-Naumescu
Ioachim Preda-Naumescu, BS, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
1 shared publication - Andrea L. DeMaria
Department of Public Health, Purdue University, West Lafayette, USA
1 shared publication Andrew Villa
1 shared publication
Latest Publications
- 11 November 2024
- Published by Springer Nature in Molecular Psychiatry
- Vol. 30 (5) , 2152-2167
Neural stem and progenitor cells support and protect adult hippocampal function via vascular endothelial growth factor secretion
Adult neural stem and progenitor cells (NSPCs) reside in the dentate gyrus (DG) of the hippocampus throughout the lifespan of most mammalian species. In addition to generating new neurons, NSPCs may alter their niche via secretion of growth factors and cytokines. We recently showed that adult DG NSPCs secrete vascular endothelial growth factor (VEGF), which is critical for maintaining adult neurogenesis. Here, we asked whether NSPC-derived VEGF alters hippocampal function independent of adult neurogenesis. We found that loss of NSPC-derived VEGF acutely impaired hippocampal memory, caused neuronal hyperexcitability and exacerbated excitotoxic injury. Conversely, we observed that overexpression of VEGF reduced microglial response to excitotoxic injury. We also found that NSPCs generate substantial proportions of total DG VEGF and VEGF disperses widely throughout the DG, both of which help explain how this anatomically-restricted cell population could modulate function broadly. These findings suggest that NSPCs actively support and protect DG function via secreted VEGF, thereby providing a non-neurogenic functional dimension to endogenous NSPCs.
- 11 November 2024
- Published by Springer Nature in Molecular Psychiatry
- Vol. 30 (5) , 2152-2167
Neural stem and progenitor cells support and protect adult hippocampal function via vascular endothelial growth factor secretion
Adult neural stem and progenitor cells (NSPCs) reside in the dentate gyrus (DG) of the hippocampus throughout the lifespan of most mammalian species. In addition to generating new neurons, NSPCs may alter their niche via secretion of growth factors and cytokines. We recently showed that adult DG NSPCs secrete vascular endothelial growth factor (VEGF), which is critical for maintaining adult neurogenesis. Here, we asked whether NSPC-derived VEGF alters hippocampal function independent of adult neurogenesis. We found that loss of NSPC-derived VEGF acutely impaired hippocampal memory, caused neuronal hyperexcitability and exacerbated excitotoxic injury. Conversely, we observed that overexpression of VEGF reduced microglial response to excitotoxic injury. We also found that NSPCs generate substantial proportions of total DG VEGF and VEGF disperses widely throughout the DG, both of which help explain how this anatomically-restricted cell population could modulate function broadly. These findings suggest that NSPCs actively support and protect DG function via secreted VEGF, thereby providing a non-neurogenic functional dimension to endogenous NSPCs.
- 26 July 2022
- Published by Elsevier in Journal of Affective Disorders
- Vol. 315, 13-16
The effect of IV ketamine in patients with major depressive disorder and elevated features of borderline personality disorder
- 26 July 2022
- Published by Elsevier in Journal of Affective Disorders
- Vol. 315, 13-16
The effect of IV ketamine in patients with major depressive disorder and elevated features of borderline personality disorder
- 29 April 2021
- Published by Springer Nature in Academic Psychiatry
- Vol. 45 (6) , 772-773
Do You Play?
- 9 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S309
Patient education for prenatal aneuploidy testing using a chatbot: a multicenter randomized controlled trial
- 9 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S309
Patient education for prenatal aneuploidy testing using a chatbot: a multicenter randomized controlled trial
- Open Access
- 7 January 2021
- Published by Frontiers Media SA in Frontiers in Psychology
- Vol. 11
Virtual Reality Reward Training for Anhedonia: A Pilot Study
Anhedonia is a risk factor for suicide and poor treatment response in depressed individuals. Most evidence-based psychological therapies target symptoms of heightened negative affect (e.g., negative inferential style) instead of deficits in positive affect (e.g., attenuated reward response) and typically show little benefit for anhedonia. Viewing positive scenes through virtual reality (VR) has been shown to increase positive affect and holds great promise for addressing anhedonic symptoms. In this pilot study, six participants with clinically significant depression completed 13 sessions of exposure to positive scenes in a controlled VR environment. Significant decreases were found in self-reported anhedonia, depression, anxiety, and impairments in functioning from baseline to 1-month follow-up. Negative affect decreased over all 13 sessions, and positive affect increased over sessions 8–13. Results suggest that positive experiences in VR may be a novel avenue for the treatment of anhedonia in depressed individuals.
- 7 January 2021
- Published by Frontiers Media SA in Frontiers in Psychology
- Vol. 11
Open AccessVirtual Reality Reward Training for Anhedonia: A Pilot Study
Anhedonia is a risk factor for suicide and poor treatment response in depressed individuals. Most evidence-based psychological therapies target symptoms of heightened negative affect (e.g., negative inferential style) instead of deficits in positive affect (e.g., attenuated reward response) and typically show little benefit for anhedonia. Viewing positive scenes through virtual reality (VR) has been shown to increase positive affect and holds great promise for addressing anhedonic symptoms. In this pilot study, six participants with clinically significant depression completed 13 sessions of exposure to positive scenes in a controlled VR environment. Significant decreases were found in self-reported anhedonia, depression, anxiety, and impairments in functioning from baseline to 1-month follow-up. Negative affect decreased over all 13 sessions, and positive affect increased over sessions 8–13. Results suggest that positive experiences in VR may be a novel avenue for the treatment of anhedonia in depressed individuals.
- Open Access
- 1 January 2021
- Published by Wiley in Journal of Ophthalmology
- Vol. 2021 (1)
Real‐World Outcomes in Patients with Branch Retinal Vein Occlusion‐ (BRVO‐) Related Macular Edema Treated with Anti‐VEGF Injections Alone versus Anti‐VEGF Injections Combined with Focal Laser
The purpose of this study was to assess outcomes in a real‐world nonclinical trial setting of antivascular endothelial growth factor (VEGF) injections alone vs. focal laser combined with anti‐VEGF injections in patients with branch retinal vein occlusion‐ (BRVO‐) related macular edema (ME). This study included 88 BRVO with ME patients who were treated over three years at both a tertiary referral center in the Birmingham metropolitan area and satellites in rural Alabama. One group received only anti‐VEGF injections ( n = 56); the other group received both anti‐VEGF injections and focal laser ( n = 32). The following outcome measures were evaluated: initial and final visual acuities (VA), initial central subfield thickness (CST) on OCT, number of injections, number of lasers, percentage of patients with a gain of 3 lines of VA, percentage of patients with VA better than or equal to 20/40, and percentage of patients with VA worse than or equal to 20/200. We found that there was no difference in initial VA ( p = 0.913) or CST ( p = 0.961) between the two groups. The injection only group required a median of 7 injections, while the combination group required a median of 4 injections, but this was not a statistically significant difference ( p = 0.117). There was no difference in final VA ( p = 0.414) or any of the other visual outcomes between the two groups. In conclusion, focal laser did not decrease the number of injections required or improve the VA in BRVO‐related ME. Although visual outcomes were similar in both groups, focal laser does not appear to be of additional benefit in BRVO‐related ME in the anti‐VEGF era.
- 1 January 2021
- Published by Wiley in Journal of Ophthalmology
- Vol. 2021 (1)
Open AccessReal‐World Outcomes in Patients with Branch Retinal Vein Occlusion‐ (BRVO‐) Related Macular Edema Treated with Anti‐VEGF Injections Alone versus Anti‐VEGF Injections Combined with Focal Laser
The purpose of this study was to assess outcomes in a real‐world nonclinical trial setting of antivascular endothelial growth factor (VEGF) injections alone vs. focal laser combined with anti‐VEGF injections in patients with branch retinal vein occlusion‐ (BRVO‐) related macular edema (ME). This study included 88 BRVO with ME patients who were treated over three years at both a tertiary referral center in the Birmingham metropolitan area and satellites in rural Alabama. One group received only anti‐VEGF injections ( n = 56); the other group received both anti‐VEGF injections and focal laser ( n = 32). The following outcome measures were evaluated: initial and final visual acuities (VA), initial central subfield thickness (CST) on OCT, number of injections, number of lasers, percentage of patients with a gain of 3 lines of VA, percentage of patients with VA better than or equal to 20/40, and percentage of patients with VA worse than or equal to 20/200. We found that there was no difference in initial VA ( p = 0.913) or CST ( p = 0.961) between the two groups. The injection only group required a median of 7 injections, while the combination group required a median of 4 injections, but this was not a statistically significant difference ( p = 0.117). There was no difference in final VA ( p = 0.414) or any of the other visual outcomes between the two groups. In conclusion, focal laser did not decrease the number of injections required or improve the VA in BRVO‐related ME. Although visual outcomes were similar in both groups, focal laser does not appear to be of additional benefit in BRVO‐related ME in the anti‐VEGF era.
- 3 April 2019
- Published by Taylor & Francis in Women's Reproductive Health
- Vol. 6 (2) , 141
PCOS
(2019). PCOS. Women's Reproductive Health: Vol. 6, No. 2, pp. 141-141.
- 3 April 2019
- Published by Taylor & Francis in Women's Reproductive Health
- Vol. 6 (2) , 141
PCOS
(2019). PCOS. Women's Reproductive Health: Vol. 6, No. 2, pp. 141-141.